|
| 35176488 | Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling. | J Mol Diagn | 2022 |
| 36466856 | Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients. | Front Immunol | 2022 |
| 36462464 | Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations. | ESMO Open | 2022 |
| 35871236 | Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing. | Br J Cancer | 2022 |
| 36050473 | Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. | Nature | 2022 |
| 33218975 | Clinicogenomic Analysis of <i>FGFR2</i>-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib. | Cancer Discov | 2021 |
| 34269576 | Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor. | J Med Chem | 2021 |
| 32315352 | INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. | PLoS One | 2020 |
| 32585295 | Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment. | Clin Immunol | 2020 |
| 32422235 | Nascent transcript and single-cell RNA-seq analysis defines the mechanism of action of the LSD1 inhibitor INCB059872 in myeloid leukemia. | Gene | 2020 |
| 32345620 | Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase <i>δ</i> Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy. | J Pharmacol Exp Ther | 2020 |
| 30206163 | The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies. | Clin Cancer Res | 2019 |
| 29127109 | INCB040093 Is a Novel PI3K<i>δ</i> Inhibitor for the Treatment of B Cell Lymphoid Malignancies. | J Pharmacol Exp Ther | 2018 |
| 27789678 | Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. | Haematologica | 2017 |
| 28456851 | Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. | Ann Hematol | 2017 |
| 28523098 | INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. | ACS Med Chem Lett | 2017 |
| 25682576 | Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. | Clin Lymphoma Myeloma Leuk | 2015 |
| 26123031 | Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor. | Br J Dermatol | 2015 |
| 26228487 | The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. | Blood | 2015 |
| 25063672 | The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. | Drug Metab Dispos | 2014 |
| 23537216 | Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. | Genet Test Mol Biomarkers | 2013 |
| 21459966 | Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection. | J Pharmacol Exp Ther | 2011 |
| 21677670 | Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. | J Invest Dermatol | 2011 |
| 20363976 | Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. | J Immunol | 2010 |
| 20556206 | Phosphorylation State-Dependent High Throughput Screening of the c-Met Kinase. | Curr Chem Genomics | 2010 |
| 20130243 | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. | Blood | 2010 |
| 20154217 | Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis. | Blood | 2010 |
| 20124451 | Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. | Mol Cancer Ther | 2010 |
| 20197554 | Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. | Blood | 2010 |
| 19507862 | Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. | J Med Chem | 2009 |
| 19887489 | Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity. | Clin Cancer Res | 2009 |
| 18037290 | Isothiazolidinone inhibitors of PTP1B containing imidazoles and imidazolines. | Bioorg Med Chem Lett | 2008 |
| 17097290 | Benzothiazole benzimidazole (S)-isothiazolidinone derivatives as protein tyrosine phosphatase-1B inhibitors. | Bioorg Med Chem Lett | 2007 |
| 17256836 | Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer. | J Med Chem | 2007 |
| 17351185 | High-throughput determination of mode of inhibition in lead identification and optimization. | J Biomol Screen | 2007 |
| 16627989 | Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. | Cancer Biol Ther | 2006 |
| 17028182 | Structural insights into the design of nonpeptidic isothiazolidinone-containing inhibitors of protein-tyrosine phosphatase 1B. | J Biol Chem | 2006 |
| 16769216 | Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: synthesis and structure-activity relationships of a peptide scaffold. | Bioorg Med Chem | 2006 |
| 16789735 | Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic. | J Med Chem | 2006 |
| 16916797 | Structural basis for inhibition of protein-tyrosine phosphatase 1B by isothiazolidinone heterocyclic phosphonate mimetics. | J Biol Chem | 2006 |
| 16210643 | Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. | J Immunol | 2005 |
| 16220970 | Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics. | J Med Chem | 2005 |
| 12798359 | Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivo. | J Steroid Biochem Mol Biol | 2003 |
| 11773073 | Absence of post-translational aspartyl beta-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia. | J Biol Chem | 2002 |
| 12163133 | Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor alpha. | J Steroid Biochem Mol Biol | 2002 |
| 12239098 | Dexamethasone and tumor necrosis factor-alpha act together to induce the cellular inhibitor of apoptosis-2 gene and prevent apoptosis in a variety of cell types. | Endocrinology | 2002 |
| 12392761 | Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). | Matrix Biol | 2002 |
| 12065438 | CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. | Drug Metab Dispos | 2002 |
| 12062799 | Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. | Gene | 2002 |
| 11676612 | A comprehensive system for protein purification and biochemical analysis based on antibodies to c-myc peptide. | Protein Expr Purif | 2001 |